These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25953139)

  • 1. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs.
    Mishra P; Murray J; Birnkrant D
    Hepatology; 2015 Oct; 62(4):1298-303. PubMed ID: 25953139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
    Shah N; Pierce T; Kowdley KV
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
    Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
    Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's meeting of Antiviral Drugs Advisory Committee.
    AIDS Alert; 2006 Oct; 21(10):118-9. PubMed ID: 17063593
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
    Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
    Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
    [No Abstract]   [Full Text] [Related]  

  • 11. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations.
    Sherman KE; Fleischer R; Laessig K; Murray J; Tauber W; Birnkrant D;
    Hepatology; 2007 Dec; 46(6):2014-20. PubMed ID: 18027878
    [No Abstract]   [Full Text] [Related]  

  • 13. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir for the treatment of hepatitis C.
    Forestier N; Zeuzem S
    Expert Opin Pharmacother; 2012 Mar; 13(4):593-606. PubMed ID: 22332992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.